Our pipeline

LNC Therapeutics
programs & projects

Our strategy:

Stablor®  program

Building on the promising results of OBEMINALE 1, a confirmatory study – dubbed OBEMINALE 2 – was launched in 2018, aimed at obtaining an EFSA 13(5) health claim for Stablor® in 2020 and then licensing-out the product to a commercial partner


Bring the first drug based on the Christensenella minuta gut bacteria targeting obesity and metabolic disorders into the first clinical trial planned for 2020


Unlock the potential of the Christensenellaceae family of bacteria via our dedicated platform, in order to identify new therapeutic applications


Incubate and maturate microbiome-related exploratory projects likely to become new drug candidates to expand our pipeline

Microbiome & us
Nov 5, 2019
LNC Therapeutics Announces Formation of its Scientific Advisory Board | Appoints international experts with...
> more
Oct 22, 2019
LNC Therapeutics chooses Luina Bio for the development and GMP manufacturing of its first live bio therapeutic product...
> more
Press / Media
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Sep 5, 2019
Capital increase supported by the Company’s historic shareholders, including Seventure Partners and a new family office...
> more
Jan 11, 2019
Comparison of the Gut Microbiota of Centenarians in Longevity Villages of South Korea with Those of Other Age Groups...
> more
Jan 2, 2019
Gut Microbes and Health: A Focus on the Mechanisms Linking Microbes, Obesity, and Related Disorders   Marialetizia...
> more
now on twitter
LNC Therapeutics

Researchers have found that people with a certain type of bacteria in their gut may be at a greater risk of develop… t.co/e4xFiNRkA2

LNC Therapeutics © 2019 - all rights reserved terms and conditions